We're not fully back to that great optimism we had a couple of years ago: Seigerman on pharma sector

Key Concepts

• Eli Lilly: A US drug maker that has seen its stock rise due to strong performance in its weight loss and diabetes drugs.
• Mounjaro & Zepbound: Eli Lilly's key drugs for diabetes and obesity, respectively.
• Orforglipron: Eli Lilly's small molecule drug expected to launch next year.
• Novo Nordisk: A competitor to Eli Lilly, also in the diabetes and obesity drug market, which has been cutting guidance.
• GLP-1s: A class of drugs, including Mounjaro and Zepbound, used for diabetes and obesity.
• Metabolic Franchise: Refers to a company's business focused on metabolic diseases, such as weight loss, MASH (metabolic dysfunction-associated steatohepatitis), fatty liver disease, and diabetes.
• Gilead: A company with a long-acting prevention treatment for HIV and strong growth in its core HIV business.
• AbbVie (Abby): A company performing well in its inflammation business with drugs like Skyrizi and Rinvoq, and also showing strength in oncology.
• Beimo Capital Markets: The firm where Evan Sigman is a managing director.

Eli Lilly's Strong Performance and Market Position

Eli Lilly has experienced a significant stock increase, driven by its strong third-quarter results. The company raised its full-year guidance, primarily due to revenue exceeding expectations from its weight loss and diabetes drugs, Mounjaro and Zepbound. Evan Sigman, managing director at Beimo Capital Markets, highlights that Eli Lilly continues to "dominate in this market well ahead of their competitor Novo Nordisk."

Key Points:

• Drug Performance: Mounjaro (diabetes) and Zepbound (obesity) are performing exceptionally well.
• Guidance Increase: Eli Lilly raised its full-year earnings and revenue guidance, signaling confidence in its future performance.
• Market Dominance: The company is positioned ahead of competitors like Novo Nordisk in the obesity and diabetes drug market.
• Comprehensive Strategy: Eli Lilly is focused on servicing all market segments, from its upcoming small molecule drug, Orforglipron (expected next year), to its current GLP-1 offerings like Mounjaro and Zepbound, and even higher efficacy products on the horizon. This strategy emphasizes self-focus rather than reacting to competitive dynamics like Novo Nordisk's M&A activities.
• Focus on Access and Growth: Eli Lilly's strategy prioritizes ensuring market access and continued market growth.

Competitive Landscape and Market Outlook

The market for obesity and diabetes drugs is robust, with significant room for growth. While Novo Nordisk is a key competitor, Eli Lilly's approach is distinct.

Key Points:

• Market Room: Sigman believes there is "still lots of room" in the market, indicating it is not yet saturated.
• Bifurcation with Novo Nordisk: A clear divergence is observed between Eli Lilly's performance and Novo Nordisk's, with Novo Nordisk cutting guidance. Novo Nordisk is expected to report less strong results next week.
• Novo Nordisk's M&A: Novo Nordisk has made an unsolicited bid for Metera, increasing its offer for Fizer's bid, indicating aggressive competitive moves.

Financial Highlights and Investor Sentiment

The financial results from Eli Lilly have been a key driver of positive sentiment.

Key Points:

• Beat on Key Drugs: Eli Lilly beat expectations for Zepbound and Mounjaro sales, which Sigman identifies as a crucial positive indicator.
• Confidence in GLP-1 Franchise: The raised guidance reinforces confidence in the continued acceleration of Eli Lilly's "inkerton franchise" (GLP-1s).
• Cautious Optimism in Sector: While the overall sentiment in the sector has improved compared to a couple of years ago, it remains "cautious." Companies are expected to continue delivering strong results.

Regulatory and Pricing Considerations

Several regulatory and pricing factors are being closely watched, particularly concerning GLP-1s.

Key Points:

• Potential Fizer-like Deal: There is anticipation for a deal similar to the one involving Fizer, potentially involving Eli Lilly and Novo Nordisk.
• Pricing Clarity Needed: Investors are seeking clarity on how GLP-1s will be priced in Medicaid.
• Medicare Access: Potential access for GLP-1s for obesity in Medicare is another area of focus.
• Compounded Drugs: A desire to see an end to compounded drugs that have been problematic for both Eli Lilly and, more specifically, Novo Nordisk.
• Uncertain Timeline: The timeline for any potential regulatory decisions or agreements is uncertain ("TBD"), with possibilities ranging from immediate to several months away.

Eli Lilly's "Metabolic Franchise"

The term "metabolic franchise" is used to describe Eli Lilly's business segment focused on metabolic diseases.

Key Points:

• Definition: This includes Eli Lilly's diabetes and obesity products, specifically their GLP-1s.
• Scope: It encompasses treatments for weight loss, MASH, fatty liver disease, and diabetes.
• Strength: Eli Lilly is considered very strong in this area.

Other Top Picks in the Sector

Beyond Eli Lilly, Sigman identifies other companies with strong potential.

Key Points:

• Eli Lilly: Holds an "outperform" rating with a price target of US$930.
• Novo Nordisk: Has a "market perform" rating.
• Gilead: A top pick due to its absence from the obesity space, its long-acting HIV prevention treatment, and strong projected growth in its core HIV business through the 2030s.
• AbbVie (Abby): Another top pick, excelling in its inflammation business with Skyrizi and Rinvoq, and showing strength in oncology. AbbVie has the capacity for deals but does not necessarily need them to remain strong.

Conclusion

Eli Lilly is demonstrating robust performance in the rapidly growing obesity and diabetes drug market, driven by its key products Mounjaro and Zepbound. The company's comprehensive strategy and strong execution have led to raised guidance and a dominant market position. While the sector remains cautiously optimistic, with ongoing scrutiny of regulatory and pricing matters, Eli Lilly, along with Gilead and AbbVie, are highlighted as strong investment opportunities. The competitive landscape, particularly with Novo Nordisk, is dynamic, with M&A and market access being key areas to watch.